Soliris (eculizumab) Concentrated solution for intravenous infusion Initial U.S. Approval: 2007

Soliris (eculizumab) Concentrated solution for intravenous infusion Initial U.S. Approval: 2007

INDICATIONS AND USAGE
Soliris is a complement inhibitor indicated for:
• The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (1.1).
• The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.
The effectiveness of Soliris in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function.
DOSAGE FORMS & STRENGTHS
300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
Manufactured By: Alexion Pharmaceuticals, Inc.
Prescribing Information URL: Click Here

Access to Soliris ® (eculizumab) Concentrated solution: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. It has been developed, manufactured, and marketed by Alexion Pharmaceuticals, which had patent exclusivity until 2017.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.